Faheem Farooq1, Peter J Mogayzel2, Sophie Lanzkron3, Carlton Haywood3,4, John J Strouse5,6. 1. Deparment of Pediatrics and Medicine, Stony Brook University Hospital, Stony Brook, New York. 2. Division of Pediatric Pulmonology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Berman Institute of Bioethics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 6. Division of Pediatric Hematology/Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Abstract
Importance: Sickle cell disease (SCD) and cystic fibrosis (CF) are severe autosomal recessive disorders associated with intermittent disease exacerbations that require hospitalizations, progressive chronic organ injury, and substantial premature mortality. Research funding is a limited resource and may contribute to health care disparities, especially for rare diseases that disproportionally affect economically disadvantaged groups. Objective: To compare disease-specific funding between SCD and CF and the association between funding and research productivity. Design, Setting, and Participants: This cross-sectional study examined federal and foundation funding, publications indexed in PubMed, clinical trials registered in ClinicalTrials.gov, and new drug approvals from January 1, 2008, to December 31, 2018, in an estimated US population of approximately 90 000 individuals with SCD and approximately 30 000 individuals with CF. Main Outcomes and Measures: Federal and foundation funding, publications indexed in PubMed, clinical trial registrations, and new drug approvals. Results: From 2008 through 2018, federal funding was greater per person with CF compared with SCD (mean [SD], $2807 [$175] vs $812 [$147]; P < .001). Foundation expenditures were greater for CF than for SCD (mean [SD], $7690 [$3974] vs $102 [$13.7]; P < .001). Significantly more research articles (mean [SD], 1594 [225] vs 926 [157]; P < .001) and US Food and Drug Administration drug approvals (4 vs 1) were found for CF compared with SCD, but the total number of clinical trials was similar (mean [SD], 27.3 [6.9] vs 23.8 [6.3]; P = .22). Conclusions and Relevance: The findings show that disparities in funding between SCD and CF may be associated with decreased research productivity and novel drug development for SCD. Increased federal and foundation funding is needed for SCD and other diseases that disproportionately affect economically disadvantaged groups to address health care disparities.
Importance: Sickle cell disease (SCD) and cystic fibrosis (CF) are severe autosomal recessive disorders associated with intermittent disease exacerbations that require hospitalizations, progressive chronic organ injury, and substantial premature mortality. Research funding is a limited resource and may contribute to health care disparities, especially for rare diseases that disproportionally affect economically disadvantaged groups. Objective: To compare disease-specific funding between SCD and CF and the association between funding and research productivity. Design, Setting, and Participants: This cross-sectional study examined federal and foundation funding, publications indexed in PubMed, clinical trials registered in ClinicalTrials.gov, and new drug approvals from January 1, 2008, to December 31, 2018, in an estimated US population of approximately 90 000 individuals with SCD and approximately 30 000 individuals with CF. Main Outcomes and Measures: Federal and foundation funding, publications indexed in PubMed, clinical trial registrations, and new drug approvals. Results: From 2008 through 2018, federal funding was greater per person with CF compared with SCD (mean [SD], $2807 [$175] vs $812 [$147]; P < .001). Foundation expenditures were greater for CF than for SCD (mean [SD], $7690 [$3974] vs $102 [$13.7]; P < .001). Significantly more research articles (mean [SD], 1594 [225] vs 926 [157]; P < .001) and US Food and Drug Administration drug approvals (4 vs 1) were found for CF compared with SCD, but the total number of clinical trials was similar (mean [SD], 27.3 [6.9] vs 23.8 [6.3]; P = .22). Conclusions and Relevance: The findings show that disparities in funding between SCD and CF may be associated with decreased research productivity and novel drug development for SCD. Increased federal and foundation funding is needed for SCD and other diseases that disproportionately affect economically disadvantaged groups to address health care disparities.
Authors: Calia A Morais; Edwin N Aroke; Janelle E Letzen; Claudia M Campbell; Anna M Hood; Mary R Janevic; Vani A Mathur; Ericka N Merriwether; Burel R Goodin; Staja Q Booker; Lisa C Campbell Journal: J Pain Date: 2022-02-26 Impact factor: 5.383
Authors: Janelle E Letzen; Vani A Mathur; Mary R Janevic; Michael D Burton; Anna M Hood; Calia A Morais; Staja Q Booker; Claudia M Campbell; Edwin N Aroke; Burel R Goodin; Lisa C Campbell; Ericka N Merriwether Journal: J Pain Date: 2022-02-26 Impact factor: 5.383
Authors: Julie Kanter; Shannon Phillips; Alyssa M Schlenz; Martina Mueller; Mary Dooley; Logan Sirline; Robert Nickel; Robert Clark Brown; Lee Hilliard; Cathy L Melvin; Robert J Adams Journal: J Pediatr Hematol Oncol Date: 2021-11-01 Impact factor: 1.289
Authors: Chris Mead; K Supriya; Yi Zheng; Ariel D Anbar; James P Collins; Paul LePore; Sara E Brownell Journal: PLoS One Date: 2020-12-11 Impact factor: 3.240
Authors: Seethal A Jacob; Roua Daas; Anna Feliciano; Julia E LaMotte; Aaron E Carroll Journal: BMC Health Serv Res Date: 2022-02-22 Impact factor: 2.655
Authors: E Fuller Torrey; Michael B Knable; A John Rush; Wendy W Simmons; John Snook; D J Jaffe Journal: PLoS One Date: 2020-11-19 Impact factor: 3.240